Tolerability & Safety of Premarin Vaginal Cream in Indian Postmenopausal Women

This study has been completed.

First Received: June 7, 2007 Last Updated: December 20, 2007 History of Changes

Sponsor:	Wyeth
Information provided by:	Wyeth
ClinicalTrials.gov Identifier:	NCT00484107

Purpose

This post-marketing study will provide local safety and tolerance data on the use of Premarin® vaginal cream.

Condition	Intervention	Phase
Postmenopause	Drug: Conjugated Estrogen Cream (Premarin®)	Phase IV

Study Type:	Observational
Official Title:	A Postmarketing Surveillance Study Evaluating the Tolerability and Safety of PREMARIN VAGINAL CREAM in Indian Postmenopausal Women

Resource links provided by NLM:

Drug Information available for: Estrogens, conjugated

Further study details as provided by Wyeth:

Eligibility

Criteria

Inclusion Criteria:

Patients in whom Premarin vaginal cream is indicated.
In the opinion of the investigator, sufficient intelligence and motivation for the patient to continue throughout the study.
Provide signed informed consent.

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00484107

Sponsors and Collaborators

Wyeth

Investigators

Study Director:

Medical Monitor

Wyeth

More Information

No publications provided

Study ID Numbers:	0713V-101833
Study First Received:	June 7, 2007
Last Updated:	December 20, 2007
ClinicalTrials.gov Identifier:	NCT00484107 History of Changes
Health Authority:	India: Ministry of Health

Additional relevant MeSH terms:

Estrogens
Estrogens, Conjugated (USP)
Physiological Effects of Drugs

Hormones, Hormone Substitutes, and Hormone Antagonists
Hormones
Pharmacologic Actions

ClinicalTrials.gov processed this record on March 18, 2010